mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
The vaccine reportedly thwarted the cancer's return and spread.
Ars Technica
First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Ars Technica.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Ars Technica (arstechnica.com), a Tier B publisher, filed this report on .
Signal breakdown
CurrentWire ranked this story 33.7 of 100 in the snapshot this page was rendered from.
- Freshness
- 4.2 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 3.5 of 10
- Story prominence
- 8 of 10
- Velocity
- 0 of 5
Strongest signal: story prominence, 8 of 10. How each signal is calculated.
Filed under Health · International · News.
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.